UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Risque de transmission du virus de l'hépatite C lors d'une endoscopie digestive

La Presse médicale (1983), 1999-06, Vol.28 (20), p.1091-1094

OUZAN, D

1999

Volltextzugriff (PDF)

1108 SELECTION OF HCV GENOTYPE 1 PATIENTS FOR DUAL THERAPY WITH PEGINTERFERON ALFA-2A/RIBAVIRIN WITH A HIGH PROBABILITY OF SUSTAINED VIROLOGIC RESPONSE ACCORDING TO BASELINE CHARACTERISTICS ALONE

Journal of hepatology, 2012-04, Vol.56, p.S436-S436

2012

Volltextzugriff (PDF)

424 OPTIMIZED HBsAg TITER MONITORING IMPROVES INTERFERON THERAPY IN PATIENTS WITH CHRONIC HEPATITIS DELTA

Journal of hepatology, 2013-04, Vol.58, p.S173-S173

2013

Volltextzugriff (PDF)

Retreatment with Direct Active Antivirals of genotype 1, 3 and 4 chronic hepatitis C patients who previously failed an anti-NS5A-containing regimen in real world

Journal of hepatology, 2017, Vol.66 (1), p.S730-S731

2017

Volltextzugriff (PDF)

Retreatment of hepatitis C virus daa failures in real life: easy and difficult to cure patients

Journal of hepatology, 2017, Vol.66 (1), p.S304-S304

2017

Volltextzugriff (PDF)

Effectiveness of Peginterferon Alfa-2a Therapy in HBeAg-Positive and HBeAg-Negative Patients with Chronic Hepatitis B: Final Results 3 Years Post-Treatment of the Prospective, Global, Observational S-Collate Study

Journal of hepatology, 2016, Vol.64 (2), p.S598-S599

2016

Volltextzugriff (PDF)

Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies

Journal of viral hepatitis, 2006-10, Vol.13 (10), p.659-670

2006

Volltextzugriff (PDF)

Prevalence and Characterization of NS5A Resistance Associated Variants in Patients who Relapsed following Exposure to NS5A Inhibitors

Journal of hepatology, 2016, Vol.64 (2), p.S408-S408

2016

Volltextzugriff (PDF)

AVDLIB 2: News Direct-Acting Antiviral (DDA) in HCV Patients with Advanced Liver Disease. Final Results of a the Second Multicenter Prospective Observational Study in Real Life Practice in France

Journal of hepatology, 2016, Vol.64 (2), p.S400-S401

2016

Volltextzugriff (PDF)

Efficacy and Safety of IFN Free, Direct-Acting Antiviral-Based Treatment Regimens in Patients with Advanced Liver Disease: Community Treatment of a Real World Population in France

Journal of hepatology, 2016, Vol.64 (2), p.S401-S401

2016

Volltextzugriff (PDF)

Viral Suppression is Not a risk Factor for CKD in Viral Cirrhosis (ANRS CO12 CirVir Prospective Cohort)

Journal of hepatology, 2016, Vol.64 (2), p.S256-S256

2016

Volltextzugriff (PDF)

New Recommendations of Baveno Vi Conference for the Screening of Portal Hypertension: An Independent Sequential Validation in Patients with Compensated Viral Cirrhosis Taking into Account Virological Status (Anrs Co12 Cirvir Cohort)

Journal of hepatology, 2016, Vol.64 (2), p.S178-S178

2016

Volltextzugriff (PDF)

The Benefits of Virosuppression on Progression of Portal Hypertension in Patients with Compensated Viral Cirrhosis (ANRS CO12 CirVir Cohort)

Journal of hepatology, 2016, Vol.64 (2), p.S655-S656

2016

Volltextzugriff (PDF)

Extrahepatic Cancer is the Second Cause of Non Liver-Related Death in Patients with Compensated Viral Cirrhosis and is Associated with Viral Replication (ANRS CO12 CirVir Prospective Cohort)

Journal of hepatology, 2016, Vol.64 (2), p.S273-S273

2016

Volltextzugriff (PDF)

Prospective Evidence That Hepatocellular Carcinoma Surveillance in Patients with Compensated Viral Cirrhosis Increases the Probability of Curative Treatment and Survival Taking into Account Lead-Time Bias (Anrs Co12 Cirvir Cohort)

Journal of hepatology, 2016, Vol.64 (2), p.S194-S195

2016

Volltextzugriff (PDF)

P0328 : Incidence, characteristics and determinants of primary liver cancer occurring during surveillance of compensated HCV cirrhosis according to sustained virological response (ANRS CO12 CirVir)

Journal of hepatology, 2015-04, Vol.62, p.S432-S432

2015

Volltextzugriff (PDF)

P0822 : Safety And efficacy of sofosbuvir containing regimens for hepatitis C: Community treatment of a real world population with advanced liver fibrosis

Journal of hepatology, 2015-04, Vol.62, p.S645-S645

2015

Volltextzugriff (PDF)

P1062 3-YEAR TREATMENT WITH TENOFOVIR IN REAL-LIFE IS EFFECTIVE AND WELL TOLERATED IN CHB PATIENTS, INCLUDING THE ELDERLY AND PATIENTS WITH COMORBIDITIES

Journal of hepatology, 2014-04, Vol.60 (1), p.S431-S431

2014

Volltextzugriff (PDF)

Optimized stepwise combination algorithms of non‐invasive liver fibrosis scores including Hepascore in hepatitis C virus patients

Alimentary pharmacology & therapeutics, 2008-08, Vol.28 (4), p.458-467

2008

Volltextzugriff (PDF)

P1061 LONG-TERM TREATMENT WITH TENOFOVIR IN TREATMENT-NAIVE OR -EXPERIENCED CHB PATIENTS IS EFFECTIVE AND WELL TOLERATED IN REAL-LIFE PRACTICE: 3 YEARS RESULTS OF THE VIREAL STUDY

Journal of hepatology, 2014-04, Vol.60 (1), p.S430-S430

2014

Volltextzugriff (PDF)

112 INCIDENCE AND PREDICTIVE FACTORS OF HEPATOCELLULAR CARCINOMA AND COMPLICATIONS IN HBV- OR HCV-RELATED COMPENSATED CIRRHOSIS. A MULTICENTER PROSPECTIVE COHORT IN 1653 PATIENTS (ANRS CO12 CirVir)

Journal of hepatology, 2013-04, Vol.58, p.S50-S50

2013

Volltextzugriff (PDF)

P1266 : Human albumin use in cirrhotic patients in France: Results of the national “Albu-live” survey

Journal of hepatology, 2015-04, Vol.62, p.S833-S833

2015

Volltextzugriff (PDF)

P723 FALDAPREVIR PLUS PEGYLATED INTERFERON/RIBAVIRIN DID NOT INCREASE ANAEMIA COMPARED WITH PEGYLATED INTERFERON/RIBAVIRIN IN HCV GENOTYPE-1, TREATMENT-NAIVE PATIENTS: POOLED ANALYSIS OF PHASE III STUDIES

Journal of hepatology, 2014-04, Vol.60 (1), p.S310-S311

2014

Volltextzugriff (PDF)

P724 VIROLOGICAL RESPONSE IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION RECEIVING FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IS UNAFFECTED BY RIBAVIRIN DOSE REDUCTION

Journal of hepatology, 2014-04, Vol.60 (1), p.S311-S311

2014

Volltextzugriff (PDF)

Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono‐infected compared with HIV–HCV co‐infected patients

Alimentary pharmacology & therapeutics, 2009-07, Vol.30 (1), p.61-70

2009

Volltextzugriff (PDF)

1 – 25 von 335

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(271)
Mit Volltextzugriff
(264)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Risque de transmission du virus de l'hépatite C lors d'une endoscopie digestive

1108 SELECTION OF HCV GENOTYPE 1 PATIENTS FOR DUAL THERAPY WITH PEGINTERFERON ALFA-2A/RIBAVIRIN WITH A HIGH PROBABILITY OF SUSTAINED VIROLOGIC RESPONSE ACCORDING TO BASELINE CHARACTERISTICS ALONE

424 OPTIMIZED HBsAg TITER MONITORING IMPROVES INTERFERON THERAPY IN PATIENTS WITH CHRONIC HEPATITIS DELTA

Retreatment with Direct Active Antivirals of genotype 1, 3 and 4 chronic hepatitis C patients who previously failed an anti-NS5A-containing regimen in real world

Retreatment of hepatitis C virus daa failures in real life: easy and difficult to cure patients

Effectiveness of Peginterferon Alfa-2a Therapy in HBeAg-Positive and HBeAg-Negative Patients with Chronic Hepatitis B: Final Results 3 Years Post-Treatment of the Prospective, Global, Observational S-Collate Study

Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies

Prevalence and Characterization of NS5A Resistance Associated Variants in Patients who Relapsed following Exposure to NS5A Inhibitors

AVDLIB 2: News Direct-Acting Antiviral (DDA) in HCV Patients with Advanced Liver Disease. Final Results of a the Second Multicenter Prospective Observational Study in Real Life Practice in France

Efficacy and Safety of IFN Free, Direct-Acting Antiviral-Based Treatment Regimens in Patients with Advanced Liver Disease: Community Treatment of a Real World Population in France

Viral Suppression is Not a risk Factor for CKD in Viral Cirrhosis (ANRS CO12 CirVir Prospective Cohort)

New Recommendations of Baveno Vi Conference for the Screening of Portal Hypertension: An Independent Sequential Validation in Patients with Compensated Viral Cirrhosis Taking into Account Virological Status (Anrs Co12 Cirvir Cohort)

The Benefits of Virosuppression on Progression of Portal Hypertension in Patients with Compensated Viral Cirrhosis (ANRS CO12 CirVir Cohort)

Extrahepatic Cancer is the Second Cause of Non Liver-Related Death in Patients with Compensated Viral Cirrhosis and is Associated with Viral Replication (ANRS CO12 CirVir Prospective Cohort)

Prospective Evidence That Hepatocellular Carcinoma Surveillance in Patients with Compensated Viral Cirrhosis Increases the Probability of Curative Treatment and Survival Taking into Account Lead-Time Bias (Anrs Co12 Cirvir Cohort)

P0328 : Incidence, characteristics and determinants of primary liver cancer occurring during surveillance of compensated HCV cirrhosis according to sustained virological response (ANRS CO12 CirVir)

P0822 : Safety And efficacy of sofosbuvir containing regimens for hepatitis C: Community treatment of a real world population with advanced liver fibrosis

P1062 3-YEAR TREATMENT WITH TENOFOVIR IN REAL-LIFE IS EFFECTIVE AND WELL TOLERATED IN CHB PATIENTS, INCLUDING THE ELDERLY AND PATIENTS WITH COMORBIDITIES

Optimized stepwise combination algorithms of non‐invasive liver fibrosis scores including Hepascore in hepatitis C virus patients

P1061 LONG-TERM TREATMENT WITH TENOFOVIR IN TREATMENT-NAIVE OR -EXPERIENCED CHB PATIENTS IS EFFECTIVE AND WELL TOLERATED IN REAL-LIFE PRACTICE: 3 YEARS RESULTS OF THE VIREAL STUDY

112 INCIDENCE AND PREDICTIVE FACTORS OF HEPATOCELLULAR CARCINOMA AND COMPLICATIONS IN HBV- OR HCV-RELATED COMPENSATED CIRRHOSIS. A MULTICENTER PROSPECTIVE COHORT IN 1653 PATIENTS (ANRS CO12 CirVir)

P1266 : Human albumin use in cirrhotic patients in France: Results of the national “Albu-live” survey

P723 FALDAPREVIR PLUS PEGYLATED INTERFERON/RIBAVIRIN DID NOT INCREASE ANAEMIA COMPARED WITH PEGYLATED INTERFERON/RIBAVIRIN IN HCV GENOTYPE-1, TREATMENT-NAIVE PATIENTS: POOLED ANALYSIS OF PHASE III STUDIES

P724 VIROLOGICAL RESPONSE IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION RECEIVING FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IS UNAFFECTED BY RIBAVIRIN DOSE REDUCTION

Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono‐infected compared with HIV–HCV co‐infected patients

Suchergebnisse filtern